Prospective Randomized Evaluation of Implantable Cardioverter-Defibrillator Programming in Patients With a Left Ventricular Assist Device

Travis D Richardson, Leslie Hale, Christopher Arteaga, Meng Xu, Mary Keebler, Kelly Schlendorf, Matthew Danter, Ashish Shah, JoAnn Lindenfeld, Christopher R Ellis, Travis D Richardson, Leslie Hale, Christopher Arteaga, Meng Xu, Mary Keebler, Kelly Schlendorf, Matthew Danter, Ashish Shah, JoAnn Lindenfeld, Christopher R Ellis

Abstract

Background: Ventricular arrhythmias are common in patients with left ventricular assist devices (LVADs) but are often hemodynamically tolerated. Optimal implantable cardioverter defibrillator (ICD) tachy-programming strategies in patients with LVAD have not been determined. We sought to determine if an ultra-conservative ICD programming strategy in patients with LVAD affects ICD shocks.

Methods and results: Adult patients with an existing ICD undergoing continuous flow LVAD implantation were randomized to standard ICD programming by their treating physician or an ultra-conservative ICD programming strategy utilizing maximal allowable intervals to detection in the ventricular fibrillation and ventricular tachycardia zones with use of ATP. Patients with cardiac resynchronization therapy (CRT) devices were also randomized to CRT ON or OFF. Patients were followed a minimum of 6 months. The primary outcome was time to first ICD shock. Among the 83 patients studied, we found no statistically significant difference in time to first ICD shock or total ICD shocks between groups. In the ultra-conservative group 16% of patients experienced at least one shock compared with 21% in the control group (P=0.66). There was no difference in mortality, arrhythmic hospitalization, or hospitalization for heart failure. In the 41 patients with CRT ICDs fewer shocks were observed with CRT-ON but this was not statistically significant: 10% of patients with CRT-ON (n=21) versus 38% with CRT-OFF (n=20) received shocks (P=0.08).

Conclusions: An ultra-conservative programming strategy did not reduce ICD shocks. Programming restrictions on ventricular tachycardia and ventricular fibrillation zone therapy should be reconsidered for the LVAD population. The role of CRT in patients with LVAD warrants further investigation.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01977703.

Keywords: cardiac resynchronization therapy; implantable cardioverter defibrillator; left ventricular assist device.

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.

Figures

Figure 1
Figure 1
Randomization strategy and enrollment. CCU indicates cardiac critical care unit; CRT, cardiac resynchronization therapy; LVAD, left ventricular assist device.
Figure 2
Figure 2
Kaplan–Meier analysis of time to first implantable cardioverter‐defibrillator (ICD) shock as well as survival in patients randomized to an ultra‐conservative ICD programming strategy vs programming at the discretion of their treating physician.

References

    1. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp‐Channing N, Davidson‐Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD‐HeFT) Investigators . Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
    1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
    1. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940.
    1. The AVID Investigators . A comparison of antiarrhythmic‐drug therapy with implantable defibrillators in patients resuscitated from near‐fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1584.
    1. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882–1890.
    1. Group M‐HS . Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in‐congestive heart failure (MERIT‐HF). Lancet. 1999;353:2001–2007.
    1. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device‐based therapy of cardiac rhythm abnormalities. Circulation. 2013;127:e283–e352.
    1. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, Morgan JA, Arabia F, Bauman ME, Buchholz HW, Deng M, Dickstein ML, El‐Banayosy A, Elliot T, Goldstein DJ, Grady KL, Jones K, Hryniewicz K, John R, Kaan A, Kusne S, Loebe M, Massicotte MP, Moazami N, Mohacsi P, Mooney M, Nelson T, Pagani F, Perry W, Potapov EV, Eduardo Rame J, Russell SD, Sorensen EN, Sun B, Strueber M, Mangi AA, Petty MG, Rogers J; International Society for Heart and Lung Transplantation . The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant. 2013;32:157–187.
    1. Enriquez AD, Calenda B, Miller MA, Anyanwu AC, Pinney SP. The role of implantable cardioverter‐defibrillators in patients with continuous flow left ventricular assist devices. Circ Arrhythm Electrophysiol. 2013;6:668–674.
    1. Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, Koene R, Cogswell R, Anand I, Roukoz H. Implantable cardioverter‐defibrillator use in patients with left ventricular assist devices: a systematic review and meta‐analysis. JACC Heart Fail. 2016;4:772–779.
    1. Cantillon DJ, Tarakji KG, Kumbhani DJ, Smedira NG, Starling RC, Wilkoff BL. Improved survival among ventricular assist device recipients with a concomitant implantable cardioverter‐defibrillator. Heart Rhythm. 2010;7:466–471.
    1. Garan AR, Yuzefpolskaya M, Colombo PC, Morrow JP, Te‐Frey R, Dano D, Takayama H, Naka Y, Garan H, Jorde UP, Uriel N. Ventricular arrhythmias and implantable cardioverter‐defibrillator therapy in patients with continuous‐flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol. 2013;61:2542–2550.
    1. Agrawal S, Garg L, Nanda S, Sharma A, Bhatia N, Manda Y, Singh A, Fegley M, Shirani J. The role of implantable cardioverter‐defibrillators in patients with continuous flow left ventricular assist devices—a meta‐analysis. Int J Cardiol. 2016;222:379–384.
    1. Ambardekar AV, Allen LA, Lindenfeld J, Lowery CM, Cannon AP, Cleveland JC, Brieke A, Sauer WH. Implantable cardioverter‐defibrillator shocks in patients with a left ventricular assist device. J Heart Lung Transplant. 2010;29:771–776.
    1. Cantillon DJ, Saliba WI, Wazni OM, Kanj M, Starling RC, Tang WHW, Wilkoff BL. Low cardiac output associated with ventricular tachyarrhythmias in continuous‐flow LVAD recipients with a concomitant ICD (LoCo VT Study). J Heart Lung Transplant. 2014;33:318–320.
    1. Healy C, Viles‐Gonzalez JF, Sacher F, Coffey JO, d'Avila A. Management of ventricular arrhythmias in patients with mechanical ventricular support devices. Curr Cardiol Rep. 2015;17:59.
    1. Fitzgibbon J, Kman NE, Gorgas D. Asymptomatic sustained polymorphic ventricular tachycardia in a patient with a left ventricular assist device: case report and what the emergency physician should know. J Emerg Med. 2016;50:e135–e141.
    1. Oz MC, Rose EA, Slater J, Kuiper JJ, Catanese KA, Levin HR. Malignant ventricular arrhythmias are well tolerated in patients receiving long‐term left ventricular assist devices. J Am Coll Cardiol. 1994;24:1688–1691.
    1. Kociol RD. Time for MADIT‐VAD? JACC Heart Fail. 2016;4:780–782.
    1. Kutyifa V. Is there a need for an implantable cardioverter defibrillator in patients with left ventricular assist devices? Time for MADIT‐VAD! Expert Rev Med Devices. 2016;14:1–2.
    1. Gopinathannair R, Birks EJ, Trivedi JR, McCants KC, Sutton BS, Deam AG, Slaughter MS, Hottigoudar RU. Impact of cardiac resynchronization therapy on clinical outcomes in patients with continuous‐flow left ventricular assist devices. J Card Fail. 2015;21:226–232.
    1. Schleifer JW, Mookadam F, Kransdorf EP, Nanda U, Adams JC, Cha S, Pajaro OE, Steidley DE, Scott RL, Carvajal T, Saadiq RA, Srivathsan K. Effect of continued cardiac resynchronization therapy on ventricular arrhythmias after left ventricular assist device implantation. Am J Cardiol. 2016;118:556–559.
    1. Barsheshet A, Wang PJ, Moss AJ, Solomon SD, Al‐Ahmad A, McNitt S, Foster E, Huang DT, Klein HU, Zareba W, Eldar M, Goldenberg I. Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT‐CRT (Multicenter Automatic Defibrillator Implantation Trial‐Cardiac Resynchronization Therapy). J Am Coll Cardiol. 2011;57:2416–2423.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever